The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma

J Hepatol. 2010 May;52(5):698-704. doi: 10.1016/j.jhep.2009.12.024. Epub 2010 Mar 4.

Abstract

Background & aims: Bcl-xL, an anti-apoptotic member of the Bcl-2 family, is over-expressed in human hepatocellular carcinoma, conferring a survival advantage to tumour cells. The mechanisms underlying its dysregulation have not been clarified. In the present study, we explored the involvement of microRNAs that act as endogenous sequence-specific suppressors of gene expression.

Methods: The expression profiles of microRNAs in Huh7 hepatoma cells and primary human hepatocytes were compared by microarray analysis. The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay. The involvement of let-7 microRNAs in human tissues was analysed by western blot and reverse transcription-PCR.

Results: Microarray analysis, followed by in silico target prediction, identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes, as well as possessing a putative target site in the bcl-xl mRNA. Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines. Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA. Human hepatocellular carcinoma tissues with low expression of let-7c displayed higher expression of Bcl-xL protein than those with high expression of let-7c, suggesting that low let-7 microRNA expression contributes to Bcl-xL over-expression. Finally, expression of let-7c enhanced apoptosis of hepatoma cells upon exposure to sorafenib, which downregulates expression of another anti-apoptotic Bcl-2 protein, Mcl-1.

Conclusions: let-7 microRNAs negatively regulate Bcl-xL expression in human hepatocellular carcinomas and induce apoptosis in cooperation with an anti-cancer drug targeting Mcl-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects*
  • Base Sequence
  • Benzenesulfonates / pharmacology
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Cyclin G1 / genetics
  • Down-Regulation / drug effects
  • Drug Synergism
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / pathology
  • MicroRNAs / genetics*
  • MicroRNAs / therapeutic use*
  • Niacinamide / analogs & derivatives
  • Oligonucleotide Array Sequence Analysis
  • Phenylurea Compounds
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • RNA, Messenger / genetics
  • RNA, Neoplasm / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sorafenib
  • Staurosporine / pharmacology
  • Up-Regulation / drug effects
  • bcl-X Protein / drug effects
  • bcl-X Protein / genetics*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Cyclin G1
  • Enzyme Inhibitors
  • MicroRNAs
  • Phenylurea Compounds
  • Pyridines
  • RNA, Messenger
  • RNA, Neoplasm
  • bcl-X Protein
  • Niacinamide
  • Sorafenib
  • Staurosporine